Work

Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.7_suppl.410

Authors: Mario Sznol, David F. McDermott, Suzanne Fields Jones, James Walter Mier, Daniel Waterkamp, Cheryl Rossi, Jeffrey Wallin, Roel Peter Funke, Johanna C. Bendell

Institutions: Yale University, Beth Israel Deaconess Medical Center, Sarah Cannon, Tennessee Oncology, F. Hoffmann-La Roche AG, Genentech

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2204966689

Cites:

Cited by: 46

Related to: 10